Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly heritable neuropsychiatric disorder. Despite the high heritability, the unraveling of specific genetic factors related to ADHD is hampered by its considerable genetic complexity. Recent evidence suggests that gene-gene interactions can explain part of this complexity. We examined the impact of strongly supported interaction effects between the LPHN3 gene and the NTAD gene cluster (NCAM1-TTC12-ANKK1-DRD2) in a 7-year follow-up of a clinical sample of adults with ADHD, addressing associations with susceptibility, symptomatology and stability of diagnosis. The sample comprises 548 adults with ADHD and 643 controls. Entropy-based analysis indicated a potential interaction between the LPHN3-rs6551665 and TTC12-rs2303380 SNPs influencing ADHD symptom counts. Further analyses revealed significant interaction effects on ADHD total symptoms (p = 0.002), and with hyperactivity/ impulsivity symptom counts (p = 0.005). In the group composed by predominantly hyperactive/impulsive and combined presentation, the presence of LPHN3-rs6551665 G allele was related to increased ADHD risk only in individuals carrying the TTC12-rs2303380 AA genotype (p = 0.026). Also, the same allelic constellation is involved in maintenance of ADHD in a predominantly hyperactive/impulsive or combined presentation after a 7-year follow-up (p = 0.008). These observations reinforce and replicate previous evidence suggesting that an interaction effect between the LPHN3 gene and the NTAD cluster may have a role in the genetic substrate associated to ADHD also in adults. Moreover, it is possible that the interactions between LPHN3 and NTAD are specific factors contributing to the development of an ADHD phenotype with increased hyperactivity/impulsivity that is maintained throughout adulthood.
Introduction
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly heritable neuropsychiatric disorder, characterized by an impairing pattern of behavior resulting in issues in social, educational or work-related settings (APA, 2013) . ADHD seems to result from the combination of effects from several genes, the interactions between them, and the interplay with the environment (Stergiakouli and Thapar, 2010) . Results derived from genome-wide association studies (GWAS) so far have shown that common genetic variability is responsible for approximately 25% of the variance in ADHD case-control status (CrossDisorder Group of the Psychiatric Genomics Consortium et al., 2013) , but they are still far away from explaining ADHD's approximate 80% heritability estimates derived from twin studies (Chang et al., 2013; Faraone et al., 2005) . Moreover, the high genetic heterogeneity of psychiatric disorders challenges the identification of the specific genetic factors related to their etiology and at the present moment no genomewide significant hits were reported for ADHD (Neale et al., 2010; Zayats et al., 2015) . Contributing to the discrepancy between the disorder's estimated heritability from twin and family studies and the explained heritability by common SNPs is the presence of interactions between genetic factors, which have been neglected in most studies (Rovaris et al., 2013; Zuk et al., 2012) . Recently, data from a large meta-analysis of heritability estimates suggested that ADHD can be depicted as an exception to the purely additive heritability model, and considered as a psychiatric disorder for which non-additive genetic factors are suggested (Polderman et al., 2015) . Such role of non-additive genetic factors on ADHD is in agreement with previous important findings involving gene-gene interactions on the etiology of the disorder (Acosta et al., 2011; Jain et al., 2012) .
One notable example of non-additive genetic effects on ADHD susceptibility refers to the interaction between the LPHN3 gene and a haplotype spanning the NCAM1, TTC12, ANKK1 and DRD2 genes, a region known as the NTAD gene cluster (Jain et al., 2012) . The concurrent presence of the LPHN3 risk allele and the NTAD risk haplotype increased in more than two-fold the risk of ADHD and influenced the response to treatment with methylphenidate (Jain et al., 2012) . Afterwards, it was also shown that interactions involving LPHN3 and the NTAD cluster were involved in predicting symptom severity in patients with the disorder (Acosta et al., 2011) , and its effect on ADHD susceptibility was replicated in an independent sample (Bruxel et al., 2015) .
Interestingly, both loci have outstanding support for their involvement in psychiatry, either from linkage studies implicating LPHN3 and NTAD in ADHD (Arcos-Burgos et al., 2004) , from candidate gene association studies repeatedly implicating the LPHN3 gene in ADHD (Acosta et al., 2016; Arcos-Burgos et al., 2010; Bruxel et al., 2015; Choudhry et al., 2012; Gomez-Sanchez et al., 2016; Hwang et al., 2015; Ribasés et al., 2011) or relating the NTAD cluster to Substance Use Disorder (Bidwell et al., 2015; David et al., 2010; Ducci et al., 2011; Gelernter et al., 2006; Lobo et al., 2012; Nelson et al., 2013; Yang et al., 2008 Yang et al., , 2007 , and even from GWAS, where the DRD2 (a member of the NTAD cluster), one of the most traditional candidates in psychiatric genetics, corresponds to one of the significant hits in the latest Schizophrenia GWAS meta-analysis (Schizophrenia Working Group of the Psychiatric Genomics Consortium et al., 2014) .
Thus, considering the strength of the evidence on the effects of the LPHN3-NTAD cluster interactions on ADHD susceptibility (Acosta et al., 2011; Bruxel et al., 2015; Jain et al., 2012) and that previous studies have evaluated either genetically isolated populations or clinical samples of children with ADHD, our aim was to further elucidate the extent of such effects for the first time in a clinical sample of adults with ADHD. We examined ADHD susceptibility, overall and domain specific symptomatology, as well as stability of diagnosis throughout adulthood in a 7-year follow-up.
Materials and methods

Study participants
The ADHD sample comprises 548 adults recruited from the Adult Division of the ADHD Outpatient Clinic at the Hospital de Clínicas de Porto Alegre (HCPA). Diagnostic procedures followed DSM-IV criteria for ADHD (APA, 1994) and were carried out by trained psychiatrists through application of clinical and semi-structured interviews, as the Portuguese version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic version (K-SADS-E), adapted to the adult life context (Grevet et al., 2005) . Other lifetime psychiatric comorbidities were assessed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (First and Gibbon, 2004) . Individuals included in this study were 18 years or older and fulfilled ADHD diagnosis criteria both currently and during childhood (retrospectively). Individuals were excluded if they presented clinically significant history of neurological disease (e.g., delirium, dementia, epilepsy, head trauma, multiple sclerosis), past or present symptoms of psychosis and/or an estimated IQ < 70. Regarding ethnicity all individuals are white Brazilians of primarily European descent. In this sense, rather than only relying on self-classification, individuals were included in the study if they reported having grandparents of European descent and the interviewer reported a morphological classification based on skin color and other morphological traits in accordance with their self-report. Considering that even the general regional population has over 90% of European ancestry according to genomic estimates of interethnic admixture (Ruiz-Linares et al., 2014) , the possibility of population stratification biases is negligible as previously reported (Zembrzuski et al., 2006) . Detailed sample characteristics are presented in Table 1 .
A subset of the ADHD sample was reassessed in a 7-year clinical follow-up of ADHD later in their adulthood, and a full description of demographic and clinical variables of this study is published elsewhere (Karam et al., 2017 . Clinical ADHD presentation for those with persistent ADHD after 7-year follow-up was available for 148 subjects.
A sample of 643 adults with negative screening for ADHD in the 6-question Adult ADHD Self-Rated Scale Screener (ASRS) v1.1 (Kessler et al., 2005) composes our control group. Individuals were recruited at the blood donation center of the same hospital where cases were ascertained. The inclusion and exclusion criteria were similar to the ADHD group, with the exception of lack of DSM-IV ADHD diagnosis (Table 1) . Presence of other psychiatric disorders was assessed with the Structured Clinical Interview for DSM-IV screening module-SCID-I/P for Axis I psychiatric disorders (First et al., 2002) .
This work was carried out in accordance with the Declaration of Helsinki and all participants signed an informed consent form approved by the Ethics Committee of HCPA (Institutional Review Board number 0000921).
Genotyping and SNP selection
We selected polymorphisms that were previously implicated in ADHD susceptibility, symptoms severity, clinical heterogeneity and/or had evidence of functionality, had a minor allele frequency > 15% and commercially validated TaqMan assays. The studied genetic polymorphisms were rs6551665 at the LPHN3 gene, which was associated to ADHD in a previous meta-analyses (Arcos-Burgos et al., 2010) , and seven SNPs spanning the NTAD gene cluster, as described elsewhere : rs646558 (NCAM1), rs723077 and rs2303380 (T-TC12), rs2734849 and rs1800497 (ANKK1), rs6277 and rs2283265 (DRD2). All SNPs were genotyped by TaqMan allelic discrimination Neuropsychopharmacology & Biological Psychiatry 79 (2017) 120-127 assays according to manufacturer's specifications (Applied Biosystems, Foster City, USA.). NTAD gene cluster SNPs had been genotyped previously in part of the sample . Genotypes were grouped in dominant models according to the frequency of each SNPs alleles (heterozygotes were combined with the less frequent homozygotes) in order to minimize the number of cells with insufficient sample size. A complete description of genotypic and allelic frequencies for all polymorphisms can be found in Supplementary Table 1 .
Statistical analyses
Firstly, different statistical models have been suggested and employed in the detection of gene-gene interaction effects (Cordell, 2009; McKinney et al., 2006; Steen, 2012) . These models include both genetic model-based and model-free methods used to evaluate the complete set of potential interactions involved in the genetic architecture of determined outcome. Model-based approaches calculate interactions based on linear and logistic regression models, while model-free assessments use data mining and machine learning approaches; each of these statistical principles presents their own specific strengths and limitations at identifying interacting genetic factors. We adopted a model-free approach using entropy-based analyses implemented in MDR v3.0.2 (Moore and Andrews, 2015) to select potential interactions between SNPs from the LPHN3 gene and the NTAD gene cluster contributing to the evaluated phenotypes. We examined the contribution of all possible pairwise genotypic connections between the LPHN3 gene and the NTAD gene cluster SNPs in relation to ADHD susceptibility and also undertook a dimensional approach by examining their effects on ADHD symptom counts within ADHD cases. Entropy-based analyses are represented in graphic networks (Kamada-Kawaii graph) showing the amount of information gain provided by each SNP (nodes) and by all pairwise combinations (lines connecting nodes) to the outcome. The calculated information gain for the pairwise combinations excludes the main effect information gain, in order to select only significant pairwise effects that are not artifacts of strong main effects (Hu et al., 2011) . The Kamada-Kawaii network was created for 8 vertices with an edge adjustment to include all SNPs (LPHN3 and NTAD cluster) in the graph. From these analyses, potential pairwise connections could be selected and further explored with appropriate adjustments for covariates (defined as described below).
Based on the overall results from the entropy-based analyses described above, we then performed Analysis of Covariance (ANCOVA) to evaluate the effect of the appointed potential interactions on total ADHD symptom counts as well as on inattention and hyperactivity/ impulsivity domains separately. Variables such as sex, age and common comorbid psychiatric disorders (i.e. Major Depressive Disorder, Generalized Anxiety Disorder, Bipolar Disorder, Oppositional Defiant Disorder and Substance Use Disorder) were considered as possible covariates and included in the model when associated at a level of p < 0.2 with both the outcome and at least one of the tested SNPs. As a third step, logistic regression analyses were performed to assess the effect of significant SNP-SNP interactions on ADHD susceptibility subdividing the cases according to their DSM-IV ADHD presentations in individuals with high hyperactivity/impulsivity symptom scores (i.e. those of predominantly hyperactive/impulsive and combined presentations -6 or more symptoms of hyperactivity/impulsivity) and with low scores (i.e. those of predominantly inattentive presentationfewer than 6 symptoms of hyperactivity/impulsivity).
Lastly, considering recent evidence implicating variants in the LPHN3 gene in a refined phenotype with stability of ADHD presentation from childhood to adolescence (Acosta et al., 2016) , we evaluated the effects of significant interactions (specifically the empirically suggested risk allelic constellations) regarding ADHD presentation on a 7-year follow-up with Fisher's Exact Test. This approach was adopted considering that the current sample with longitudinal data is still relatively small to test interaction effects by means of logistic regression. False discovery rate (FDR) approach was applied to account for the multiple tests performed and false discovery rate significance threshold was set to 5% (Benjamini et al., 1995) .
Although not in the original scope of this study, main effects for the LPHN3-rs6551665 regarding ADHD susceptibility in this sample have been tested in order to enable the inclusion of these results in future meta-analyses. Main effects regarding ADHD symptomatology can be found in Table 2 , and further detailed results are presented in Supplementary Table 2 . The effects of NTAD cluster SNPs in this sample have been previously reported .
Results
Entropy-based LPHN3-NTAD interaction analyses: ADHD symptoms and diagnosis in adults
We conducted a model-free entropy-based analysis in order to assess the effects of previously reported LPHN3-NTAD interactions on ADHD susceptibility in adults. The Kamada-Kawaii graph did not clearly suggest specific potential interactions to be taken further in-depth when evaluating case-control status in our sample ( Supplementary Fig. 1-A) . Analysis of ADHD symptom counts within cases, however, indicated a potential interaction between the evaluated LPHN3 SNP and one of the TTC12 SNPs analyzed, with an increased gain of information when evaluating both polymorphisms jointly ( Supplementary Fig. 1-B) . Independently, LPHN3-rs6551665 and TTC12-rs2303380 would account for, respectively, 0.19% and 0.08% of the observed outcome variance; while the two SNPs cooperatively explain 1.09% of ADHD total symptom counts variance. Other interactions did not show any greater information gain.
LPHN3-rs6551665-TTC12-rs2303380 interaction
Following the above interaction analyses, and in order to further understand the effects of the LPHN3-rs6551665 -TTC12-rs2303380 interaction, ANCOVA was used to evaluate its effects for total ADHD symptom counts, as well as for inattention and hyperactivity/impulsivity symptoms separately. Confounders for these analyses were presence of current Oppositional Defiant Disorder and Bipolar Disorder. The LPHN3-rs6551665 -TTC12-rs2303380 interaction was significantly associated with ADHD total symptom counts (F (1,538) = 9.40; p = 0.002; p FDR = 0.032), and with hyperactivity/impulsivity symptoms (F (1,538) = 7.969; p = 0.005; p FDR = 0.040), while the same was not observed for the inattention symptoms measure (F (1,538) = 1.288; p = 0.257; p FDR = 0.373) ( Table 2 ). The post-hoc analysis showed that, when compared to the reference allelic constellation (LPHN3-rs6551665 AA -TTC12-rs2303380 AA), the presence of LPHN3-rs6551665 G allele was associated to increased ADHD total symptoms in individuals with the TTC12-rs2303380 AA genotype (p = 0.004) but not in individuals carrying the TTC12-rs2303380 G allele (p = 0.587) (Fig. 1-A) . In order to further validate this finding as an interaction effect we compared ADHD total symptoms scores between the two groups of LPHN3-rs6551665 G allele carriers (i.e. TTC12-rs2303380 AA and TTC12-rs2303380 G +; represented by red dots in Fig. 1-A) , and found a significant difference between these two sets (p = 0.002, not shown). These results suggest that LPHN3-rs6551665 G + -TTC12-rs2303380 AA represents a distinct group from those formed by either the alternative LPHN3 genotype (reference allelic constellation) or the alternative TTC12 genotype (LPHN3-rs6551665 G + -TTC12-rs2303380 G +) groups regarding ADHD total symptoms. A similar effect was observed when only hyperactive/impulsive symptoms were considered ( Fig. 1-B) ; while no interaction effects were found when exclusively inattention symptoms were evaluated ( Fig. 1-C) . A complete description of ADHD symptoms counts according to LPHN3-rs6551665 and TTC12-rs2303380 genotypes can be found in Supplementary Table 3.
ADHD susceptibility in specific presentations
Since ANCOVA analyses showed a significant effect on ADHD symptomatology, which seems to be mostly related to the hyperactivity/impulsivity symptoms domain, we performed logistic regression in order to test the interaction on ADHD susceptibility in adults separately in those with combined or hyperactive/impulsive ADHD presentation and in those with inattentive ADHD presentation. Casecontrol analyses performed in the predominantly hyperactive/impulsive and combined group showed that there was an interaction effect, where the presence of LPHN3-rs6551665 G allele was nominally associated to increased ADHD risk in individuals carrying the TTC12-rs2303380 AA genotype (OR (CI 95% ) = 1.664 (1.062-2.606); p = 0.026; p FDR = 0.104), while there was no effect in individuals carrying the TTC12-rs2303380 G allele (OR (CI 95% ) = 1.169 (0.755-1.810); p = 0.484; p FDR = 0.590) (Fig. 1-D) . Confirming the interaction effect between the two groups of LPHN3-rs6551665 G allele carriers (TTC12-rs2303380 AA and TTC12-rs2303380 G+), there was a significant difference between these two sets (p = 0.045, not shown). The observed LPHN3 effect shows a similar pattern to the one observed for total ADHD and hyperactivity/impulsivity symptom measures. Such LPHN3-TTC12 interaction effect was not observed in the analysis regarding predominantly inattentive individuals ( Fig. 1-E) , which is also in agreement with the lack of effect observed for the inattention symptoms measure. Additional information on LPHN3-rs6551665 -T-TC12-rs2303380 cell counts in cases and controls is presented in Supplementary Table 4 .
ADHD presentation in a clinical follow-up
We performed Fisher's Exact Test in order to assess if the LPHN3-TTC12 interaction was also associated to stability of ADHD presentation during adulthood in a 7-year clinical follow-up. Given the reduced sample size with available follow-up data we tested the influence of the established risk allelic constellation (LPHN3-rs6551665 G + -TTC12-rs2303380 AA) against the other allelic combinations. Cross-tabulation demonstrated that the presence of the risk allelic constellation (LPHN3- Fig. 1 . Interaction effects for ADHD symptom counts and diagnosis. A -Mean total symptom scores according to LPHN3-rs6551665 and TTC12-rs2303380 genotypes in adults with ADHD. B -Mean symptom scores for the hyperactivity/impulsivity domain (HI) according to the LPHN3-rs6551665 and TTC12-rs2303380 genotypes. C -Mean symptom scores for the inattention domain (Inatt) according to the LPHN3-rs6551665 and TTC12-rs2303380 genotypes. D -Influence of LPHN3-rs6551665 and TTC12-rs2303380 genotypes on the susceptibility to ADHD in individuals with high hyperactivity/impulsivity symptom measures (i.e. predominantly hyperactive/impulsive and combined presentations). E -Influence of LPHN3-rs6551665 and TTC12-rs2303380 genotypes on the susceptibility to ADHD in individuals with low hyperactivity/impulsivity symptom measures (i.e. predominantly inattentive presentation).
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Progress in Neuropsychopharmacology & Biological Psychiatry 79 (2017) 120-127 rs6551665 G + -TTC12-rs2303380 AA) was significantly associated to stability of ADHD presentation (Fisher's Exact Test = 11.331; p = 0.008; p FDR = 0.042). There was an excess of expected subjects retaining diagnosis as combined or predominantly hyperactive/impulsive ADHD after follow-up, while subjects retaining diagnosis as inattentive presentation were reduced (Table 3) . Taking into account that ADHD subjects with a combined presentation report more symptoms, and this is one of the predicting factors of ADHD persistence Victor et al., 2014) , we also performed this analysis adjusting for a possible confounding effect of ADHD total symptom counts. The inclusion of such covariate did not substantially change the results.
Discussion
This study replicates previous evidence on the presence of interaction effects between LPHN3 and NTAD markers on ADHD susceptibility, expanding this finding for the first time to a clinical sample of adults. Furthermore, the present study shows that such interaction effect is restricted to hyperactivity/impulsivity symptoms within ADHD cases and, consequently, to ADHD susceptibility in hyperactive/impulsive or combined presentations only. We also provide additional evidence that this gene-gene interaction appears to be involved in the persistence of ADHD hyperactive/impulsive or combined presentations throughout adulthood. Overall, these findings suggest that a LPHN3-NTAD interaction may be involved in the underpinnings of ADHD susceptibility and stability.
In this context, we observed that, regarding hyperactivity/impulsivity symptoms and ADHD susceptibility in presentations with clear presence of hyperactivity/impulsivity symptoms, a LPHN3-TTC12 interaction could be able to modulate the LPHN3 variant effects, where the risk effect of LPHN3-rs6551665 G allele is only observable in individuals with TTC12-rs2303380 AA genotype, being abolished in the presence of TTC12-rs2303380 G allele. Meanwhile, no significant interaction effect was observed neither on inattention symptom counts in ADHD cases nor on ADHD susceptibility when individuals with predominantly inattentive presentation were analyzed separately.
Multiple studies have shown main effects of LPHN3 variants on ADHD susceptibility, most of them regarding childhood ADHD (ArcosBurgos et al., 2010; Bruxel et al., 2015; Choudhry et al., 2012; GomezSanchez et al., 2016; Hwang et al., 2015; Ribasés et al., 2011) , providing new insights into the genetics, neurobiology and treatment of ADHD. Similar to what we observed here with the LPHN3-TTC12 interaction, some of these studies have also revealed that the genetic association between LPHN3 and ADHD could be either driven by, or present only in samples of ADHD with higher presence of hyperactivity/ impulsivity (Gomez-Sanchez et al., 2016; Ribasés et al., 2011) .
Also, a recent longitudinal study was able to show that a LPHN3 polymorphism is associated with a refined ADHD phenotype characterized by maintenance of ADHD diagnosis with a combined presentation from childhood into adolescence (Acosta et al., 2016) . Similarly, here we report that the presence of the risk allelic constellation (LPHN3-rs6551665 G + -TTC12-rs2303380 AA) was associated to maintenance of ADHD presentation in the hyperactive/impulsive or combined presentations throughout adulthood in a 7-year follow-up. Interestingly, most children with ADHD have clinical characteristics of high hyperactivity/impulsivity symptomatology, but the persistence of these symptoms into adulthood seems to be less common than of the inattention symptoms (Biederman et al., 2000) . Nevertheless, adults with ADHD that show increased symptomatology on the hyperactivity/impulsivity domain refer higher presence of other psychiatric comorbidities (Cadman et al., 2016) , especially increased risk of Substance Use Disorder (Liebrenz et al., 2015) . These results implicate the LPHN3-TTC12 interaction as being involved in the development and persistence of a more externalizing form of ADHD.
The observed effect of LPHN3 and its interactions with the NTAD cluster in regulating hyperactivity/impulsivity is further supported by studies with different animal models. Animals submitted to either knockout or knockdown of LPHN3 orthologues were behaviorally characterized as having increased locomotor activity, which is comparable to the hyperactivity observed in individuals with ADHD (Lange et al., 2012; Orsini et al., 2016; Reuter et al., 2016; van der Voet et al., 2016; Wallis et al., 2012) . The behavioral hyperactivity in Drosophila was considered to be derived from abnormal dopamine-mediated signaling (van der Voet et al., 2016) , and zebrafish presented disorganized and reduced number of dopaminergic neurons (Lange et al., 2012; Reuter et al., 2016) . Additionally, Lphn3 null mice presented increased levels of dopamine in the striatum and increased expression of dopaminergic receptors (including Drd2), and other related genes, such as Ncam, another member of the NTAD cluster (Wallis et al., 2012) . Together, these findings suggest that the LPHN3 gene is implicated in regulating the development of the dopaminergic system.
Considering the central role of the dopaminergic system in the neurobiology of ADHD (Arnsten, 2009; Faraone et al., 2015; Genro et al., 2010; Purper-Ouakil et al., 2011) , particularly in the subcortical mechanisms related to motor responses, and the effects of LPHN3 in the development and regulation of dopaminergic signaling, it seems likely that the influence of the interaction between LPHN3 and TTC12 reported here can be related to changes in the subcortical dopaminergic pathways, as in the mesolimbic system. This hypothesis is interesting because it also enhances the neurodevelopmental aspects of ADHD, demonstrating that the effects of genetic variants involved in modifying the development of the central nervous system can also be detected and have persistent effects in adult subjects with the disorder.
Overall, the preponderance of the evidence supports the association between LPHN3 and ADHD; however, the TTC12 effects are much less clear. Jain et al. (2012) demonstrated that an 11q haplotype, spanning the NTAD cluster, despite showing a significant interaction effect with Neuropsychopharmacology & Biological Psychiatry 79 (2017) 120-127 LPHN3, does not exhibit main effects on ADHD susceptibility by itself. Similarly, a previous study performed on our sample did not reveal main effects of NTAD cluster SNPs on ADHD susceptibility, including the TTC12 SNPs evaluated here . In spite of the fact that TTC12 gene function remains unclear, its properties and location within the NTAD gene cluster suggest it to be involved in cell adhesion, neurogenesis and modulation of dopaminergic transmission (Katoh and Katoh, 2003; Mota et al., 2015 Mota et al., , 2012 Yang et al., 2007) . Thus, it is possible that the TTC12-rs2303380 variant is involved in TTC12-driven modulations of the dopaminergic system, that when interacting with LPHN3-rs6551665 can either counter-act or enhance the effects of the later. Our findings should be understood in the context of some limitations. First, although our sample size of adults with ADHD is moderate, the expected effect size for these interactions is small. Thus, it might be still premature to completely rule out the possibility of false-negative findings regarding other possible LPHN3-NTAD interactions. On the other hand, this is the first replication study in an adult sample but, considering the investigations in other independent samples, also providing evidence in the same direction, the overall scenario is not one of a high risk for false-positive findings. Additionally, one strength of our approach is that we departed from a model-free entropy-based method to screen for the potential interactions, and narrowed down the area of association derived from the original 11q haplotype (Jain et al., 2012) . Finally, we cannot infer the specific effects of the observed risk allele constellation since the exact molecular mechanisms and biological processes involved with these interaction effects are still unknown.
Conclusion
In conclusion, our results further contribute to the understanding of LPHN3 role in ADHD and help to elucidate its interactions with the NTAD gene cluster as a genetic substrate to ADHD clinical trajectory, extending previous childhood findings also to adulthood. Moreover, we suggest that a genetic effect shown to contribute to ADHD susceptibility may also have long-lasting effects on the development of an ADHD phenotype marked by increased and persistent hyperactivity/impulsivity. Our study thus sheds light on the biological underpinnings of ADHD and also shows the need for further studies that go beyond the case-control analysis and expand the phenotypic characterization of selected and robust genetic findings.
Supplementary data associated with this article can be found in the online version, at http://dx.doi.org/10.1016/j.pnpbp.2017.06.011.
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